Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm crizotinib study in ALK-positive advanced non-small cell lung cancer
2009-012504-13Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Objective response rate. Started Oct 2009; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-012504-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012504-13.